Regresar

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients

Abstract:

Dear Editor, Neutralizing autoantibodies (auto-Abs) against type I interferons (IFN-I) have been identified as risk factor for life-threatening coronavirus disease 2019 (COVID-19) and were described in 101 of 987 (10%) patients with life-threatening pneumonia of whom 37 (37%) died [1]. In contrast, these antibodies were not found in patients with asymptomatic or mild disease and 0.33% of healthy individuals. Auto-Abs against cytokines can cause severe or recurrent infections by neutralizing their target cytokine [2]. Auto-Abs to IFN-I without neutralizing ability in vitro have been identified in COVID-19 patients, but their clinical significance is unclear. Here we describe clinical characteristics of COVID-19 patients with auto-Abs neutralizing IFN-I, a subset of patients described by Bastard et al.[1]. In addition, we investigate the role of auto-Abs against IFN-I that were not neutralizing in vitro in COVID-19 and non-COVID-19 …